Jubilant Organosys Ltd announced on Monday that its US-based subsidiary, Clinsys Clinical Research, Inc., a global contract research organisation (CRO), has acquired TrialStat ClinicalAnalytics, a unit of TrialStat for Canadian $750,000.
TrialStat ClinicalAnalytics (TrialStat CA) is a Web-based electronic data capture (EDC) solution, currently used by a wide range of pharmaceutical and CRO customers worldwide.
Commenting on the acquisition, Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director, Jubilant Organosys Ltd, said: “The addition of the TrialStat CA and its proven EDC offering will allow Clinsys to continue to expand its integrated solutions for pharmaceutical, biotechnology and medical device organisations. This acquisition is an excellent fit and addresses the industry’s continuously evolving requirements in EDC.”
TrialStat CA is the industry’s first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively, a company statement said. The company said it had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally.
Jubilant Organosys Ltd is an integrated pharmaceutical industry player, custom research and manufacturing services and drug discovery and development services companies out of India.
The company has a presence across the pharmaceutical value chain for products and services that include exclusive synthesis arrangements, active pharmaceutical ingredients among others.